Last reviewed · How we verify
Triptorelin for Injection
Triptorelin for Injection is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist.
Triptorelin for Injection is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist. Used for Prostate cancer, Premature puberty.
At a glance
| Generic name | Triptorelin for Injection |
|---|---|
| Also known as | Gonadotropin releasing hormone agonists |
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to GnRH receptors in the pituitary gland, triptorelin triggers a cascade of downstream effects that ultimately lead to the suppression of gonadotropin secretion, resulting in decreased levels of sex hormones such as testosterone and estrogen.
Approved indications
- Prostate cancer
- Premature puberty
Common side effects
- Hot flashes
- Nausea
- Headache
- Injection site reaction
Key clinical trials
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation. (PHASE3)
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptorelin for Injection CI brief — competitive landscape report
- Triptorelin for Injection updates RSS · CI watch RSS
- Changchun GeneScience Pharmaceutical Co., Ltd. portfolio CI